Developed by Top Cancer Experts
Delfi’s team includes leading experts in cancer biology, bioinformatics, machine learning, and public health.
CEO and Founder
Dr. Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis.
Join Our Team
We’re growing rapidly across all of our teams. Find your next role at Delfi.
Cell-free DNA consists of DNA fragments released into the bloodstream when a cell is damaged or dies. They carry many clues about whether a person may have cancer.
Victor Velculescu, MD, PhD
CEO and Founder
Victor is internationally known for his discoveries in genomics and cancer research. He and his colleagues performed the first genome-wide sequence analysis in human cancers, identifying key genes and pathways dysregulated in tumorigenesis. He developed methods for global gene-expression analyses and coined the word “transcriptome” to describe the patterns that could now be obtained in cancer and other cells. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human cancer. These efforts have led to new FDA-approved therapies and diagnostic tests widely used for patients with cancer. More recently, his group has developed noninvasive liquid biopsy approaches for early detection and monitoring of patients with cancer. These discoveries provide new paradigms for our understanding of human cancer that have benefited patients worldwide.
Jenn Buechel, MSc Eng
Chief Operating Officer
Jenn brings over 20 years of experience in launching products in a wide variety of industries, with a particular focus on bringing novel healthcare technologies from R&D to market. Most recently, Jenn held product and program executive leadership roles with GRAIL and Guardant Health. Prior to her work in diagnostics, she held roles of increasing responsibility at Genentech, Amyris Biotechnology, and McKinsey. Jenn earned an MSc Eng in Systems Engineering and an MBA from Stanford University, as well as a BSc Eng in Chemical Engineering and a BA in English from Queen’s University in Canada. Active in global nonprofit and policy work, Jenn is passionate about improving the accessibility of high-quality healthcare to the most underserved populations.
Nicholas C. Dracopoli, PhD
Chief Scientific Officer and Co-founder
Nicholas brings more than 20 years of biotech and pharma experience to Delfi Diagnostics after having leadership roles at PGDx, Janssen, and Bristol-Myers Squibb in oncology translational science. Nic obtained his BSc and PhD degrees from the University of London and completed postdoctoral fellowships at the Memorial Sloan-Kettering Cancer Center and Massachusetts Institute of Technology. Subsequently, he served as Assistant Director at the Whitehead Institute/MIT Genome Center, and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health before moving to the biotechnology and pharmaceutical industry. Nic has authored more than 75 scientific publications and has extensive experience in the fields of genomics, molecular biology, and cancer research.
Peter B. Bach, MD
Chief Medical Officer
Health policy and payment expert, pulmonary physician, and lung cancer epidemiologist, Peter has devoted his career to repairing defects in the healthcare delivery system that impede access to high-quality cancer care and working to ameliorate healthcare’s cost crisis. His work spans seminal studies including that identification of racial gaps in lung cancer care, the development of the first lung cancer risk prediction model (the “Bach model”), lead authorship on multiple lung screening guidelines, and definitional work on pharmaceutical pricing and value. Peter previously served as Senior Adviser at the US Centers for Medicare & Medicaid Services and mentor on many National Institutes of Health K awards. He has been elected to the National Academy of Medicine, American Society for Clinical Investigation, and the Johns Hopkins Society of Scholars.
Monique Cadle, MA
Vice President, People
Monique is responsible for leading human resources operations, culture, learning & development, coaching, recruiting, and organizational strategy. Over the last 15 years, she has helped people and organizations thrive through her work in people operations and management consulting, as well as nonprofit management across sectors and industries. At GRAIL, Deloitte, US Agency for International Development, and 23andMe, among other organizations, she has built thriving human resources programs and initiatives with diversity, equity, and inclusion at center. Monique is an Integral Coach who studied and continues to mentor at New Ventures West. She holds an MA in Public Policy and Management from Carnegie Mellon and a Bachelor of Arts in International-Intercultural Studies from Claremont McKenna College. For the past 10 years, she’s served as a mentor with the Posse Foundation and serves as Founding Partner of Good Works Consulting. Fitness is her thing, and music makes her sing – she loves running, roller skating, skateboarding, and record collecting.
Tara Maddala, PhD
Vice President, Clinical Development
Tara has a proven track record of developing genomic diagnostic products from feasibility through commercialization. As a Vice President at GRAIL, she led a team of clinical data scientists and biosample managers responsible for designing and analyzing foundational, large-scale genomic studies, sample collection, and biobanking. At Genomic Health, she was a co-inventor of the Oncotype DX® Genomic Prostate Score assay, employing statistical machine learning for algorithm development. Tara co-invented several issued cancer genomic patents and co-authored approximately 20 peer-reviewed publications and over 40 congress presentations. She enjoys volunteering with the Bay Area Biotech-Pharma Statistical Workshop and Young Women In Bio, and coaching high school tennis. Tara holds a PhD in Biostatistics from The University of Texas and Engineering BS and MS degrees from The University of Florida and Georgia Tech.
Tobias Mann, PhD
Vice President, Software Engineering
Tobias has deep expertise and leadership experience in next-generation sequencing, bioinformatics, and regulated software development in support of clinical testing laboratories. Prior to joining Delfi, Tobias was Vice President of Software Engineering at Adaptive Biotechnologies, where he led teams developing software to support development and production implementation of immunosequencing assays to support a variety of clinical and research applications. Before Adaptive, Tobias held roles of increasing seniority at Progenity and Illumina, supporting development of products and applications of next-generation sequencing. Tobias is a passionate cook and forged his own chef’s knives after watching all too much “Forged in Fire.”
Allison Ryan, PhD
Vice President, Data Science
Allison joins Delfi with 12 years of experience developing complex algorithms for genetic testing. She has developed and launched laboratory-developed tests in clinical applications including noninvasive prenatal testing, transplanted organ health, and oncology minimal residual disease testing, leading to more than 2 million reported test results. Allison is an author on more than 20 publications and 10 issued US patents. She was previously Vice President of Data Science at Natera, where she managed a team of 30 data scientists, biostatisticians, and bioinformaticians, as well as being a founding leader of the Women’s Resource Group. Allison completed her BS, MS and PhD in Mechanical Engineering at the University of California, Berkeley as well as performing with the Cal Marching Band.
Rob Scharpf, PhD
Head of Computational Biology and Co-founder
In addition to his role at Delfi Diagnostics, Rob is Associate Professor of Oncology and Biostatistics at The Johns Hopkins University Schools of Medicine and Public Health. He received his PhD in biostatistics at Johns Hopkins and is an expert in developing statistical methods and software for high-throughput genomic data analysis, including machine-learning models for cancer detection and Bayesian approaches for modeling batch effects, data integration, and cancer risk. He was the recipient of the Director’s Award for Teaching from the Sidney Kimmel Cancer Center in Philadelphia and the Margaret Merrell Award for Outstanding Research as a PhD student. His publications have appeared in leading scientific, statistical, and epidemiologic journals, including Nature and the Journal of the American Statistical Association.
Timothy McDaniel, PhD
Vice President, Technology Development
Tim brings three decades of genomics research, product development, and diagnostics experience to Delfi Diagnostics. Prior to Delfi, as a senior vice president at TGen, he oversaw Ashion Analytics, a diagnostics laboratory, acquired by Exact Sciences in 2021. Before that he was at Illumina, where he led programs to develop the company’s core next-generation sequencing consumables, launching more than 25 products and helping to grow the company from a startup into the world’s leading genomic sequencing technology provider. A molecular biologist by training, Tim was a Damon Runyon Postdoctoral Fellow at Stanford and earned his PhD from the University of Maryland, Baltimore and BA from UC Santa Barbara.
Chief Financial Officer
Doug was most recently Managing Director and Senior Analyst at Cowen. At Cowen, he led the Life Science & Diagnostics Tools franchise, which he established in 2007. In this role, he covered approximately 50 companies over 20 years, was recognized by groups including but not limited to Institutional Investor as one of the top analysts in the sector, and established thought leadership via deep-dive fundamental research in areas including liquid biopsy testing and next-generation sequencing. Previously, Doug worked in venture capital and crossover investing at Global Biomedical Partners, and in private equity at Triumph Capital. He began his career as an investment banker at Cowen after earning a BS in Business Administration from Georgetown University. Doug graduated with an MBA from the Anderson School of Business at UCLA.